Latest news with #diabetesmanagement
Medscape
9 hours ago
- Health
- Medscape
Can Behavioral Support Enhance CGM Use in T1D?
TOPLINE: Behavioral support for first-time users of a continuous glucose monitoring (CGM) device showed no significant difference in reduction of A1c levels compared with CGM alone in the management of type 1 diabetes (T1D). Adults in both groups reported reduced diabetes distress. METHODOLOGY: Automated insulin delivery systems are the standard of care for adults with T1D, and using them requires both an insulin pump and a CGM device. A randomized controlled trial was conducted to assess the use of CGM among 134 adults with T1D who had not previously used CGM (mean age, 35 years; 77% women; 55% not using an insulin pump) who were recruited from clinics and T1D organizations across the United States. Participants were randomly assigned to one of two groups: one received CGM alone and the other received CGM plus the ONBOARD behavioral intervention, both for 3 months. The ONBOARD intervention included four 60-minute virtual, 1:1 biweekly sessions to address barriers related to wearing the device, data management, social concerns, and trust. Changes in A1c levels and diabetes distress scores were evaluated using t-tests and linear mixed-effect models over 12 months. TAKEAWAY: At 12 months after initiating CGM, 80% of participants in the ONBOARD group and 71% in the CGM-only group reported using CGM. Both the CGM-only and ONBOARD groups showed significant reductions in A1c levels (P < .05), with no significant difference between the groups. Participants in both groups experienced significant and clinically meaningful decreases in diabetes distress (P < .001). The CGM-only group showed greater reductions in diabetes distress than the ONBOARD group at 3 months; reductions were similar between groups at 6 and 12 months. IN PRACTICE: "Findings highlight benefits of introducing CGM on diabetes management and diabetes distress for adults with T1D. Most participants were still using CGM 12 months after initiating use through the study, indicating durable uptake," the authors write. SOURCE: The study was led by Molly L. Tanenbaum, PhD, Stanford University School of Medicine, California. The poster will be presented on June 23 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center, Chicago, Illinois. LIMITATIONS: No study limitations were discussed in the abstract. DISCLOSURES: One author disclosed consulting roles with Sanofi and Havas Health, an advisory role with MannKind Corporation, and receiving research support from embecta. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Health Line
12-06-2025
- Health
- Health Line
How Do You Treat Type 1 Diabetes?
Managing type 1 diabetes means you'll have to take insulin each day. You may also work with a doctor to treat T1D with other medications in addition to insulin, and determine what else may be best for your diabetes care goals. Treating type 1 diabetes (T1D) is not as simple as just taking a particular medication or using a therapy, but it's more of a management puzzle that has many different parts. People with T1D must take insulin because their bodies do not naturally produce it. This is a required and first-line treatment for anyone with this autoimmune condition. Beyond that, people with T1D may also take other medications and use different methods to help manage their blood sugar levels. This is where your healthcare team plays a key role in helping to create a diabetes management plan and how to best treat your T1D based on many factors. Managing type 1 diabetes While the 'treatment' for a chronic condition is often viewed through the lens of medications or other therapies, T1D is one of those that requires constant management and affects how certain medications work. That is why treating T1D goes beyond just insulin and medication use. Diabetes management involves monitoring blood sugar levels, keeping track of what you consume each day, maintaining enough physical activity, managing your mental health, and more. Using insulin People with T1D must take insulin each day. Their bodies don't naturally make insulin, so it must be administered in another way. Many different types of insulin exist, ranging from fast short-acting insulin taken each time you eat or consume carbohydrates to longer-acting insulin that lasts in your body for hours at a time. Whatever type of insulin you take, you administer it through injections with a syringe or prefilled insulin pen. Others may choose to use an insulin pump device to administer their insulin each day. Insulin pens Many different types of insulin pens exist for long-acting and mealtime insulin forms. You may find these differ slightly based on the insulin you're using. Many of the most common insulin pens are disposable. They contain a prefilled cartridge that can be used for a certain number of days, and when the cartridge is empty, the entire pen is thrown away. Some reusable pens are also available, allowing you to replace the insulin cartridge when it's empty. The needles on insulin pens are known as pen needles, and they come in different lengths and thicknesses based on your preferences. Insulin pumps Insulin pumps are wearable devices that people with diabetes use to deliver insulin. They are connected to a spot on your body and continuously give insulin for 2 to 4 days. These devices deliver a programmed amount of insulin through a small tube called a cannula, inserted just under the top layer of your skin. Your doctor will work with you to determine how much insulin you need each day. Insulin pumps can also deliver an insulin bolus, which is an extra dose of insulin in addition to your basal rate. Some pumps may automatically give you boluses based on your higher blood sugar or carbs, but most allow you to enter a manual bolus for the pump to deliver when needed. Historically, insulin pumps were completely manual devices that you had to program for any insulin. In more recent years, advanced technology now available allows for algorithms to calculate and automatically deliver if you use the device with a connected CGM. Off-label medications for type 1 diabetes Other diabetes medications may also be something to discuss with your doctor. These may include Metformin, GLP-1s, or SGLT-2s meds, which aren't cleared by regulators to use with T1D but may be beneficial beyond that labeling. While some research does show the benefit of these medications for T1D, it indicates there may not be a significant blood sugar improvement, and there may be a high risk of increased hypoglycemia, hyperglycemia, and DKA. That is why it's always important to consult a doctor and your diabetes care team to discuss possible pros and cons if you're interested in using an off-label treatment for T1D along with insulin. It's also important to take all medications as prescribed. Metformin Metformin is a type of oral medication that's approved for type 2 diabetes. However, it's now also commonly prescribed by doctors, and some people with T1Ds use them successfully along with their insulin. Since some T1Ds can develop insulin resistance, the insulin they take each day may not work as well as it once did. Metformin may be an option because it helps reduce sugar production in the liver. Your doctor may advise you to take Metformin in addition to insulin, but that could mean they'd have to write an off-label prescription. GLP-1s Glucagon-like peptide-1 receptor (GLP-1) agonists help manage blood sugar levels and reduce hunger and food intake, possibly supporting weight loss along with managing diabetes glucose levels. These may include: Ozempic Wegovy Trulicity Victoza While these are FDA-cleared for those with T2D, some people with type 1 diabetes also choose to use these for the same reasons. The diabetes clinical community, along with T1Ds, has been advocating for the FDA to consider labeling these medications beyond just T2D use, but as of mid-2025, that hasn't yet materialized. SGLT-2 inhibitors Sodium-glucose transport protein 2 (SGLT2) inhibitors are a class of medications that are also known as gliflozins. These prevent glucose from reabsorbing after it's filtered through your kidneys, helping that glucose to leave your body through urine and lowering blood sugar levels. Invokana Jardiance Farxiga Steglatro This 2023 research review found moderate benefits for SGLT-2s in people type 1 diabetes, without an increase in risk or side effects. One specific SGLT-2 called Sotagliflozin (Zynquista) could eventually be used to treat T1D along with insulin. It would work to lower glucose levels by forcing the body to release it in urine and reducing glucose absorption in the gut. This 2019 research review shows the promise of the medication being used for T1D. However, the Food and Drug Administration (FDA) denied Sotagliflozin in both 2019 and 2024 due to some concerns about the medication. However, it is approved by the European Medicines Agency (EMA) and may be reconsidered by the FDA in the future. Consult your diabetes care team Managing and treating type 1 diabetes is a very individualized process that requires working with your healthcare team. They can best help you understand the condition and learn what treatments may be best for your personal diabetes management and health goals. Always consult your care team before making any treatment decisions, including the types and dosages of any medications you take. For people with T1D, this will likely include diabetes specialists, including an endocrinologist, diabetes care and education specialist, and nutritionist or dietitian. Cure research and related treatments While there isn't a T1D cure on the horizon, researchers continue studying ways to prevent this autoimmune condition and reverse it for those who've already been diagnosed. Some of the more promising research avenues currently include: Gene therapy For T1D, gene therapy could involve reprogramming alternative cells, making those reprogrammed cells perform the functions of the original insulin-producing beta cells. But the reprogrammed cells would be different enough from beta cells so that your own immune system wouldn't recognize them as 'new cells' and attack them, which is what happens in the development of T1D. Islet cell transplants This involves transplanting donated or newly created insulin-making islet cells into the body or pancreas of someone with T1D. Islet transplants aren't new and have been an experimental treatment for many years. This requires immunosuppressant drugs, which often have other side effects and are more expensive. Despite the limited promise of this therapy, many challenges exist. In 2023, the FDA approved a first-of-its-kind treatment for a small number of people with T1D who have severe hypoglycemia and struggle to maintain their blood sugars. Known as Lantrida, this is the first pancreatic islet cellular therapy made from deceased donor pancreatic cells. Other ongoing research explores using stem cells to generate new islet cells rather than transplanting them. Functional bionic therapy Largely based on technology that includes insulin pumps and continuous glucose monitors (CGM), these options to treat and manage T1D may be considered a 'functional cure' —something that basically makes life with this type of diabetes minimally burdensome and almost as 'good as being cured' for some people. These may be the evolving technologies, including closed-loop systems that automatically manage insulin and glucose monitoring to keep blood sugars in target range. Various early systems exist and are getting better, and some believe that this could eventually become a standard of care in managing T1D — assuming affordability and access allow for it. The takeaway Insulin is the main and only required treatment for type 1 diabetes. This is needed because people with T1D don't naturally make insulin in their bodies as those without the condition do. Other medications and types of therapy, alongside insulin, may also help people manage their blood sugar levels and diabetes overall. Some of these prescription medications may be considered 'off-label' drugs if your doctor is willing to prescribe them for T1D. Diabetes management means routine blood sugar monitoring, exercise and eating routines, and other aspects, from sleep to mental health.
Associated Press
27-05-2025
- Business
- Associated Press
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "Making Diabetes Management Simpler: The New Era of Insulin Therapy" Featuring Modular Medical CEO - Wednesday, May 28, 2025
SAN DIEGO, CA / ACCESS Newswire / May 27, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ('Modular Medical' or the 'Company'), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of 'almost-pumpers' with its user-friendly and affordable design, today announced that Jeb Besser, CEO of Modular Medical, will present at Tribe Public's Webinar Presentation and Q&A Event titled 'Making Diabetes Management Simpler: The New Era of Insulin Therapy."The Event is scheduled to begin at 9 a.m. pacific / 12 p.m. eastern on Wednesday, May 28, 2025. To register to join the complimentary event, please visit the Tribe Public LLC at Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at [email protected] or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management. About Modular Medical Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond 'superusers' and providing 'diabetes care for the rest of us.' Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its insulin pump. More information is available at All trademarks mentioned herein are the property of their respective owners. ABOUT TRIBE PUBLIC LLC Tribe Public LLC, headquartered in San Francisco, California, is a distinguished organization that facilitates corporate sponsored global webinars and in-person meetings events across 36 premier venues throughout the United States. Tribe Public's events are tailored to address topics of significant interest to its members, with a particular emphasis on providing direct access to management teams and leading experts from diverse sectors who seek to enhance awareness of their products, achievements, and strategic initiatives. The Tribe's membership is composed primarily of Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and media professionals, all of whom benefit from exclusive opportunities for business development, community building, and informed dialogue in a collegial setting. Members are actively encouraged to shape the event agenda by submitting speaker and company preferences through Tribe Public's complimentary 'Wish List' process on its website, ensuring that the programming reflects the evolving interests of its sophisticated community. To learn more about Tribe Public's offerings and to participate in upcoming events, visit their website at: CONTACT: Jeb Besser Chief Executive Officer Modular Medical, Inc. +1 (617) 399-1741 [email protected] SOURCE: Modular Medical, Inc. press release
Yahoo
22-05-2025
- Health
- Yahoo
U.S. and Europe Clinical Wearable Medical Devices Market Trends Analysis Report 2025-2030: Diabetes and Cardiovascular Surge Drive Adoption, Increasing Demand for Remote Monitoring
Factors include rising chronic disease prevalence and technological advances. With increasing demand for diabetes management and elderly care, the market will see significant growth in connected insulin pumps, glucose monitors, and other wearable devices. Detailed segmentation and future trends offer strategic insights for stakeholders. U.S. and European Clinical Wearable Medical Devices Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "U.S. and Europe Clinical Wearable Medical Devices Market Size, Share & Trends Analysis Report by Product (Insulin Pumps & Continuous Glucose Monitors), Application (Chronic Disease Management), Connectivity Type, End Use, with Growth Forecasts, 2025-2030" report has been added to U.S. and Europe Clinical Wearable Medical Devices Market was valued at USD 45.29 Billion in 2024, and is projected to reach USD 89.31 Billion by 2030, rising at a CAGR of 12.10% The increasing prevalence of chronic diseases like diabetes, heart disorders, and kidney disorders, along with advancements in clinical wearable medical devices, is expected to drive market growth. According to data from the American Heart Association, by June 2024, approximately 184 million individuals-over 61% of adults in the U.S.-are projected to be affected by some form of cardiovascular disorder by 2050. Such a high burden of chronic diseases is anticipated to drive the demand for clinical wearable medical devices in the coming years. The rise in the prevalence of diabetes, driven by factors such as aging, obesity, and unhealthy lifestyles, is a significant contributor to market growth. This trend is increasing the demand for convenient and effective insulin delivery methods. In addition, the growing incidence of prediabetes is also fueling market expansion. For instance, according to data published by the CDC in May 2024, approximately 38 million people in the U.S. have diabetes, while about 98 million American adults are classified as 2030, the highest prevalence of diabetes is estimated to be in Spain, followed by Germany, with the second highest prevalence, while Norway will have the lowest prevalence. The increasing rates of diabetes in various European countries and the U.S. are expected to boost the demand for clinical wearable medical devices, such as connected insulin pumps and glucose monitoring the increasing geriatric population is a significant factor driving the market for clinical wearable medical devices. Older adults are more vulnerable to chronic health conditions such as hypertension, heart disease, diabetes, and various pulmonary and neurological disorders. According to data published by the National Council on Aging, Inc. in May 2024, over 94% of individuals aged 60 and older have at least one chronic condition, while approximately 78% suffer from two or more such addition, people aged 65 and older are currently the fastest-growing segment of the U.S. population. The U.S. CDC's 2024 report projects that nearly a quarter of the population will be over 65 by 2060. Aging can weaken the immune system and increase susceptibility to various health issues, negatively impacting individuals' quality of life. Many in this age group are primarily dependent or semi-dependent, making frequent hospital visits challenging. Implementing effective strategies, such as the use of clinical wearable medical devices, can enhance the quality and longevity of life for older adults, promoting greater independence. As a result, the adoption of these devices is expected to rise among older individuals. They help them monitor key health indicators like blood pressure and respiratory rate, improving their overall health and quality of life. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 100 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $45.29 Billion Forecasted Market Value (USD) by 2030 $89.31 Billion Compound Annual Growth Rate 12.1% Regions Covered Europe, United States U.S. and Europe Clinical Wearable Medical Devices Market Variables, Trends, & Scope Market Lineage Outlook Parent Market Outlook Ancillary Market Outlook Market Driver Analysis Rising prevalence of chronic diseases Increasing geriatric population Advent of technologically advanced products Market Restraint Analysis High cost of devices and lack of reimbursement policies Product recalls Market Opportunities Analysis Growing clinical trials Increasing demand for remote monitoring Rising focus on wearable artificial kidney devices Market Challenge Analysis Accuracy and reliability U.S. and Europe Clinical Wearable Medical Devices Market Analysis Tools Industry Analysis - Porter's PESTEL Analysis U.S. and Europe Clinical Wearable Medical Devices Market Report: SegmentationProduct Outlook (Revenue, USD Million, 2018-2030) Insulin Pumps and Continuous Glucose Monitors (CGMs) Cardiac Monitors Respiratory Monitoring Devices Neurostimulators Blood Pressure Monitors Wearable Dialysis Devices Wearable Oxygen Therapy Devices Other Wearable Medical Devices Application Outlook (Revenue, USD Million, 2018-2030) Chronic Disease Management Post-operative Care Remote Patient Monitoring (RPM) Other Applications Connectivity Type Outlook (Revenue, USD Million, 2018-2030) Bluetooth-connected Wi-Fi-enabled Cellular-connected IoT-based End Use Outlook (Revenue, USD Million, 2018-2030) Home Healthcare Hospitals and Clinics Ambulatory Care Settings Other Settings Competitive Landscape Company Overview Financial Performance Product Benchmarking Strategic Initiatives Medtronic Abbott Koninklijke Philips N.V. GE HealthCare OMRON Healthcare, Inc. Dexcom, Inc. Insulet Corporation Tandem Diabetes Care, Inc. Fresenius Medical Care AG Inogen Cognita Labs AliveCor, Inc. EMAY VivaLNK, Inc. CAIRE Inc Ypsomed AG Wellue Qardio, Inc Withings iRhythm Technologies, Inc OxyGo HQ Florida, LLC. LOOKEETech VitalConnect Boston Scientific Corporation Nexstim LivaNova PLC Neuropace Inc. Nevro Corporation electroCore, Inc. tVNS Technologies GmbH Laborie Axonics, Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. and European Clinical Wearable Medical Devices Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
